Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT-Reference-Cited by-同舟云学术

Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT

Published:2017-07-28 Issue:12 Volume:106 Page:939-946
ISSN:1861-0684
Container-title:Clinical Research in Cardiology
language:en
Short-container-title:Clin Res Cardiol

Author:

Hartman Minke H. T.,Prins Jake K. B.,Schurer Remco A. J.,Lipsic Erik,Lexis Chris P. H.,van der Horst-Schrivers Anouk N. A.,van Veldhuisen Dirk J.,van der Horst Iwan C. C.,van der Harst Pim

Funder

ZonMw

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

http://link.springer.com/article/10.1007/s00392-017-1140-z/fulltext.html

Reference31 articles.

1. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van’t Hof A, Widimsky P, Zahger D (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569–2619

2. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, Anaya-Cisneros M, Tian R, Lefer DJ (2009) Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 104:403–411

3. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L, DIGAMI 2 Investigators (2011) Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the diabetes mellitus insulin-glucose infusion in acute myocardial infarction (DIGAMI) 2 Study. Diabetologia 54:1308–1317

4. Lexis CP, Wieringa WG, Hiemstra B, van Deursen VM, Lipsic E, van der Harst P, van Veldhuisen DJ, van der Horst IC (2014) Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction. Cardiovasc Drugs Ther 28:163–171

5. Rosiak M, Postula M, Kaplon-Cieslicka A, Trzepla E, Czlonkowski A, Filipiak KJ, Opolski G (2013) Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes. Adv Med Sci 58:362–368

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling genetic causality between metformin and myocardial infarction on the basis of Mendelian randomization;Frontiers in Endocrinology;2024-05-03

2. Implications and hidden toxicity of cardiometabolic syndrome and early‐stage heart failure in carfilzomib‐induced cardiotoxicity;British Journal of Pharmacology;2024-04-28

3. Effects of SGLT2-inhibitor on The Expression of MicroRNA-21, Transforming Growth Factor-β1, and Matrix Metalloproteinase-2 in The Process of Cardiac Fibrosis in Hyperglycemic Model Rats;The Indonesian Biomedical Journal;2024-02-23

4. Effects of Metformin on Ischemia/Reperfusion Injury: New Evidence and Mechanisms;Pharmaceuticals;2023-08-09

5. Metabolic complications of glucocorticoids – Prevention by metformin;Annales d'Endocrinologie;2023-08